GlassScriptPhysician profile
Ali Delbakhsh
NPI 1154365872
$4,215.42
in general payments reported to CMS, 2019-2025
30 companies · $402 in 2025
The $402 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,090 · 2020: $701 · 2021: $399 · 2022: $233 · 2023: $262 · 2024: $129 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $638.19 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $578.70 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $417.47 | 2019-2021 | |
| Boston Scientific Corporation | $298.05 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $240.16 | 2019-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $236.20 | 2019-2025 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $229.30 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $204.17 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $166.03 | 2019-2024 | Ozempic |
| Astellas Pharma US INC | $164.31 | 2024-2025 | |
| Amgen INC. | $159.28 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $132.75 | 2019-2020 | |
| Amarin Pharma, INC. | $128.02 | 2019-2020 | |
| Esperion Therapeutics, INC. | $127.90 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $51.30 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $49.00 | 2019 | |
| Abbott Laboratories | $46.28 | 2019-2020 | |
| Lundbeck LLC | $43.29 | 2019 | |
| Abiomed | $42.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.21 | 2020-2023 | Jardiance |
| Gilead Sciences, INC. | $36.98 | 2019 | |
| Medtronic, INC. | $36.75 | 2021 | |
| Scpharmaceuticals INC. | $26.40 | 2024 | |
| Medtronic Vascular, INC. | $21.73 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $19.22 | 2023 | Inpefa |
| Baxter Healthcare | $19.15 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Lilly USA, LLC | $17.62 | 2020 | |
| Merck Sharp & Dohme LLC | $16.18 | 2023 | Verquvo |
| Getinge USA Sales, LLC | $15.09 | 2019 | |
| Philips North America LLC | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Delbakhsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.